MedTrace Logo

A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient

NCT01757262 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-05-13

No results posted yet for this study

Summary

Study in Vietnamese Patients with Coronary Heart Disease to investigate safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel

Conditions

Interventions

DRUG

90 mg Ticagrelor

Morning and Evening dose for 5 days

DRUG

75mg Clopidogrel

Morning dose for 5 days

Sponsors & Collaborators

Principal Investigators

  • Nguyen Lan Viet, MD · National Heart Institute, Bach Mai Hospital, Vietnam

  • Judith Hsia, MD · Astrazeneca, Wilmington, US

  • Miriana Kujacic, MD · Astrazeneca, Molndal, Sweden

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-01-31
Primary Completion
2013-04-30
Completion
2013-04-30

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01757262 on ClinicalTrials.gov